On Friday, the United States FDA (Food and Drug Administration) has authorized a medication of Amgen Biopharmaceutical in patients with NSCLC ( Non-small cell lung cancer), who have a particular mutation in the KRAS gene, and whose condition has become worse despite being treated with chemotherapy and other medications.<\/p>\n\n\n\n
In clinical studies, the drug named sotorasib, which will be marketed as Lumakras has shown a significant reduction in tumor size with KRAS gene mutation in roughly 36% of cancer patients. The drug will cost around $17,900 per month in the United States, according to Amgen.<\/p>\n\n\n\n
This drug is specially developed to target the KRAS G12C mutated genes, which takes place in approximately 13% of NSCLC, the most prevalent type of lung cancer.<\/p>\n\n\n\n
Amgen believes that the therapy will be accessible to roughly 25,000 individuals in the United States each year. This KRAS mutation can also be detected in 1%-3% of colorectal cancer and other malignancies.<\/p>\n\n\n\n
FDA has approved a 960mg OD ( once a day) tablet, over two months before the scheduled date. Amgen is also required to do a post-approval analysis to assess the effectiveness of medication in low doses.<\/p>\n\n\n\n
Although cancer medications are designed at a greater acceptable dosage, several oncologists have encouraged the FDA to go a little further in compelling the manufacturers to improve the dosage of the drug.<\/p>\n\n\n\n
\u201cOur sense is this is going to become more common in oncology,\u201d Amgen research chief David Reese told Reuters in a phone interview.<\/p>\n\n\n\n
Lumakras is among the rising trend of targeted medications that target cancer-causing gene abnormalities, irrespective of the origin of the disease.<\/p>\n\n\n\n
Amgen is evaluating Lumakras in combination with other medications as first-line therapy for Non-small cell lung cancer patients with KRAS gene mutation, and many other cancer types, according to Reese.<\/p>\n","protected":false},"excerpt":{"rendered":"
On Friday, the United States FDA (Food and Drug Administration) has authorized a medication of Amgen Biopharmaceutical in patients with NSCLC<\/p>\n","protected":false},"author":1,"featured_media":1806,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[35,2],"tags":[410,52,61,164],"class_list":{"0":"post-1805","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-clinical","8":"category-featured","9":"tag-amgen-kras","10":"tag-cancer","11":"tag-fda","12":"tag-oncology"},"_links":{"self":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts\/1805","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/comments?post=1805"}],"version-history":[{"count":0,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts\/1805\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/media\/1806"}],"wp:attachment":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/media?parent=1805"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/categories?post=1805"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/tags?post=1805"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}